Latest News

GSK says late-stage trials of potential blockbuster asthma drug met their goals


GSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than £3 billion ($3.8 billion) met their goals.

FTSE 100 live: Blue-chips set to fall as oil prices drop

Previous article

B&Q and Screwfix owner Kingfisher sees sales fall less than expected

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News